Townsquare Capital LLC Purchases Shares of 8,126 Masimo Co. (NASDAQ:MASI)

Townsquare Capital LLC acquired a new position in shares of Masimo Co. (NASDAQ:MASI) in the fourth quarter, HoldingsChannel reports. The fund acquired 8,126 shares of the medical equipment provider’s stock, valued at approximately $1,343,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Jones Financial Companies Lllp purchased a new stake in shares of Masimo during the 4th quarter worth about $27,000. UMB Bank n.a. lifted its position in Masimo by 180.9% during the fourth quarter. UMB Bank n.a. now owns 191 shares of the medical equipment provider’s stock valued at $32,000 after buying an additional 123 shares in the last quarter. Trust Co. of Vermont purchased a new stake in Masimo during the fourth quarter worth approximately $33,000. Blue Trust Inc. increased its position in shares of Masimo by 56.3% in the fourth quarter. Blue Trust Inc. now owns 197 shares of the medical equipment provider’s stock worth $33,000 after acquiring an additional 71 shares in the last quarter. Finally, EverSource Wealth Advisors LLC raised its stake in shares of Masimo by 40.0% in the 4th quarter. EverSource Wealth Advisors LLC now owns 224 shares of the medical equipment provider’s stock valued at $37,000 after acquiring an additional 64 shares during the period. Institutional investors and hedge funds own 85.96% of the company’s stock.

Masimo Stock Performance

Shares of MASI stock opened at $152.15 on Friday. The stock has a market capitalization of $8.22 billion, a price-to-earnings ratio of 104.93 and a beta of 1.28. Masimo Co. has a one year low of $101.61 and a one year high of $194.88. The company’s 50-day simple moving average is $168.54 and its 200-day simple moving average is $164.58. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.11 and a current ratio of 2.01.

Masimo (NASDAQ:MASI) last released its earnings results on Tuesday, February 25th. The medical equipment provider reported $1.80 EPS for the quarter, topping analysts’ consensus estimates of $1.42 by $0.38. Masimo had a return on equity of 14.98% and a net margin of 3.85%. The company had revenue of $600.70 million for the quarter, compared to the consensus estimate of $593.35 million. Equities analysts anticipate that Masimo Co. will post 4.1 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on the stock. Wells Fargo & Company upped their price target on shares of Masimo from $193.00 to $205.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 26th. Needham & Company LLC reiterated a “hold” rating on shares of Masimo in a research note on Thursday, April 10th. Piper Sandler boosted their price target on Masimo from $210.00 to $215.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 26th. Finally, Raymond James increased their price objective on shares of Masimo from $170.00 to $194.00 and gave the company an “outperform” rating in a research report on Friday, December 27th. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $194.80.

Insiders Place Their Bets

In other news, Director Craig B. Reynolds sold 2,053 shares of the firm’s stock in a transaction dated Friday, March 14th. The shares were sold at an average price of $166.13, for a total value of $341,064.89. Following the transaction, the director now directly owns 16,581 shares in the company, valued at approximately $2,754,601.53. This trade represents a 11.02 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, COO Bilal Muhsin sold 30,000 shares of the business’s stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $167.49, for a total transaction of $5,024,700.00. Following the sale, the chief operating officer now directly owns 24,172 shares of the company’s stock, valued at approximately $4,048,568.28. This represents a 55.38 % decrease in their position. The disclosure for this sale can be found here. 16.90% of the stock is currently owned by corporate insiders.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.